肝细胞生长因子 | 72957-37-0

• 物质功能分类: 生物化工 - 多肽
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 肝细胞生长因子
• 中文别名: N2-(N-甘氨酰-L-组氨酰)-L-赖氨酸单乙酸盐；甘氨酰-组氨酰-赖氨酰乙酸盐
• 英文名称: Prezatide monoacetate
• 英文别名: acetic acid;(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid
• CAS: 72957-37-0
• 化学式: C16H28N6O6
• mdl: MFCD00012699
• 分子量: 400.43
• InChiKey: MGNUTAFMLGJBGV-ACMTZBLWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.1
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.562
• 拓扑面积：
  214
• 氢给体数：
  7
• 氢受体数：
  9

安全信息

• WGK Germany：
  3
• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

寡肽-1

三肽-1也称为寡肽-1，是一种低聚物，属于寡肽的一种。它自然存在于人的血液和唾液中，并由组氨酸、甘氨酸与赖氨酸缩合而成。主要作用于皮肤的真皮层，促进细胞外基质如胶原蛋白和糖胺聚糖的合成，使皮肤变得更加厚实、紧致，减少皱纹，并提高对抗紫外线的能力。

作用机理

作为信号肽，三肽-1能够有效刺激胶原蛋白和弹性蛋白的产生，增加血管生成并提升抗氧化能力。它还能促进相关生长因子的产生，帮助皮肤恢复自我修复功能。使用含有三肽-1的产品可以在不伤害肌肤、不引起刺激的情况下，增强细胞活力，并逐渐补充体内流失的胶原蛋白，从而达到除皱抗衰老的效果。

功效作用

• 保湿：作为天然保湿因子的重要组成部分，三肽-1具有极强的锁水能力。

• 抗衰：减少皱纹产生与胶原质自然流失有关。它可以直接渗透到真皮层中补充胶原蛋白，重塑皮肤纤维组织结构，恢复弹性，延缓细胞老化。

• 修护：直接作用于皮肤底层，抑制细胞变性、激发细胞活性，修复受损细胞，并清除自由基，促进胶原蛋白的生成与合成。

安全性

三肽-1在化妆品和护肤品中主要用作抗氧化剂。其风险系数为1，相对安全无刺激，没有致痘性，可以放心使用。

质量标准

外观：白色粉末 纯度（HPLC）≥98.0% 醋酸根含量5.0%～12.0% 水分含量≤8.0% 肽含量≥80.0%

文献信息

• Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
  申请人：The Interthyr Corporation

  公开号：EP2399578A1

  公开（公告）日：2011-12-28

  The present invention relates to the treatment of autoimmune and/or inflammatory diseases associated with over-expression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to the use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to treating a subject having a disease or condition associated with abnormal Toll-like receptor 3 as well as Toll-like receptor 4 and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The present invention also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. This invention also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with the Toll-like receptor overexpression or signaling.

  本发明涉及治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中Toll样受体3（TLR3）以及Toll样受体4（TLR4）和/或TLR3/TLR4信号过度表达有关的自身免疫性和/或炎症性疾病，以及相关病理。本发明还涉及苯基甲巯咪唑、甲巯咪唑衍生物和同分异构环硫代甲烷用于治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中的Toll样受体3（TLR3）以及Toll样受体4（TLR4）和/或TLR3/TLR4信号转导相关的自身免疫性和炎症性疾病。本发明还涉及治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中 Toll 样受体 3 以及 Toll 样受体 4 和/或 TLR3/TLR4 信号异常有关的疾病或病症。本发明还涉及治疗与 TLR 过度表达和信号转导相关的自身免疫炎症性病症以及趋化因子和细胞因子介导的疾病。本发明还涉及能够抑制与 Toll 样受体过度表达或信号转导相关的 IRF-3/1型 IFN/STAT/ISRE/IRF-1 通路的药物制剂。
• Immune activation by double-stranded polynucleotides
  申请人：Kohn D. Leonard

  公开号：US20050036993A1

  公开（公告）日：2005-02-17

  Double-stranded polynucleotide activates the expression of immune recognition molecules. The polynucleotide can have a minimal length and activates the expression of molecules not encoded by a nucleotide sequence that is not necessarily related to the polynucleotide. The present invention provides for a simple and specific system to activate expression of Class I and/or Class II molecules of the major histocompatibility complex (MHC), and allows regulation of expression of MHC molecules on the cell-surface of antigen presenting cells and other immune cells. Also provided are systems for the screening, identification, and isolation of compounds that increase or decrease this activation.

  双链多核苷酸可激活免疫识别分子的表达。多核苷酸可以具有最小长度，并能激活与多核苷酸不一定相关的核苷酸序列未编码的分子的表达。本发明提供了一种激活主要组织相容性复合体（MHC）I 类和/或 II 类分子表达的简单而特异的系统，可以调节抗原呈递细胞和其他免疫细胞细胞表面 MHC 分子的表达。此外，还提供了用于筛选、鉴定和分离增加或减少这种激活的化合物的系统。
• Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
  申请人：Kohn D. Leonard

  公开号：US20060211752A1

  公开（公告）日：2006-09-21

  The present invention relates to the treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to the use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to treating a subject having a disease or condition associated with abnormal Toll-like receptor 3 as well as Toll-like receptor 4 and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The present invention also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. This invention also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.

  本发明涉及治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中Toll样受体3（TLR3）以及Toll样受体4（TLR4）和/或TLR3/TLR4信号过度表达有关的自身免疫性和/或炎症性疾病，以及相关病理。本发明还涉及苯基甲巯咪唑、甲巯咪唑衍生物和同分异构环硫代甲烷用于治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中的Toll样受体3（TLR3）以及Toll样受体4（TLR4）和/或TLR3/TLR4信号转导相关的自身免疫性和炎症性疾病。本发明还涉及治疗与非免疫细胞、单核细胞、巨噬细胞和/或树突状细胞中 Toll 样受体 3 以及 Toll 样受体 4 和/或 TLR3/TLR4 信号异常有关的疾病或病症。本发明还涉及治疗与 TLR 过度表达和信号转导相关的自身免疫炎症性病症以及趋化因子和细胞因子介导的疾病。本发明还涉及能够抑制与 Toll 样受体过度表达或信号转导相关的 IRF-3/1型 IFN/STAT/ISRE/IRF-1 通路的药物制剂。
• USE OF AN MHC CLASS I SUPPRESSOR DRUG FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANTATION REJECTION
  申请人：THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：EP0702554A1

  公开（公告）日：1996-03-27
• METHODS OF ASSESSING MHC CLASS I EXPRESSION AND PROTEINS CAPABLE OF MODULATING CLASS I EXPRESSION
  申请人：THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：EP0880701A1

  公开（公告）日：1998-12-02